Bioactive Compounds of Momordica charantia L. Downregulate the Protein Expression of ACE2 and TMPRSS2 In Vivo and In Vitro
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020868 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Che-Yi Chao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Nutrition and Health Biotechnology, Asia University, Taichung 413, Taiwan. Hauptthemen laut MEDLINE: Serine Endopeptidases, Momordica charantia, Angiotensin-Converting Enzyme 2, Plant Extracts. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asia University, China Medical University, Taiwan, Asia University, Taiwan.
Abstract (Originalsprache)
The emergence of SARS-CoV-2, the etiological agent of COVID-19, has resulted in widespread global infection and millions of deaths. Viral entry is initiated by the interaction between the viral spike (S) protein and the host cell receptor ACE2, followed by TMPRSS2-mediated proteolytic activation that facilitates membrane fusion. Bitter melon (Momordica charantia L., MC), a traditional medicinal and edible plant widely used in tropical Asia, possesses notable anti-inflammatory, antioxidant, antitumor, and hypoglycemic properties. In this study, the ethanol extract of bitter melon (EMC) markedly downregulated ACE2 and TMPRSS2 expression in both in vitro and in vivo models without inducing cytotoxicity. Furthermore, phytochemicals isolated from EMC—including p-coumaric acid, rutin, and quercetin—exhibited comparable inhibitory effects. These results indicate that EMC and its bioactive constituents may interfere with SARS-CoV-2 entry by modulating the ACE2/TMPRSS2 axis, highlighting their potential as natural adjuncts for COVID-19 prevention or management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Food Nutrition and Health Biotechnology, Asia University, Taichung 413, Taiwan.
- Translational Medicine Research Center, China Medical University Hospital, Taichung 413, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 413, Taiwan.
- Department of Neurosurgery, Asia University Hospital, Taichung 413, Taiwan.
- Department of Occupational Therapy, Asia University, Taichung 413, Taiwan.
- Department of Pharmacy, China Medical University, Taichung 404, Taiwan.
ORCID-Profile: Che-Yi Chao, Chih-Lung Lin, Wen-Ping Jiang, Jaung-Geng Lin, Guan-Jhong Huang
Förderung
- Asia University
- China Medical University, Taiwan
- Asia University, Taiwan
Zitieren
APA
Chao, C. Y., Shyu, W. C., Lin, C. L., Jiang, W. P., Inose, A., Chiang, S. J., Wu, W. L., Lin, J. G., & Huang, G. J. (2026). Bioactive Compounds of Momordica charantia L. Downregulate the Protein Expression of ACE2 and TMPRSS2 In Vivo and In Vitro. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020868
Vancouver
Chao CY, Shyu WC, Lin CL, Jiang WP, Inose A, Chiang SJ, et al. Bioactive Compounds of Momordica charantia L. Downregulate the Protein Expression of ACE2 and TMPRSS2 In Vivo and In Vitro. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020868
BibTeX
@article{Chao2026,
author = {Chao, Che-Yi and Shyu, Woei-Cheang and Lin, Chih-Lung and Jiang, Wen-Ping and Inose, Atsushi and Chiang, Song-Jie and Wu, Wen-Liang and Lin, Jaung-Geng and Huang, Guan-Jhong},
title = {Bioactive Compounds of Momordica charantia L. Downregulate the Protein Expression of ACE2 and TMPRSS2 In Vivo and In Vitro},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020868}
}
EUVIMED